Menu Search
Equities

Tandem Diabetes Care Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0M0F:LSE

Tandem Diabetes Care Inc

Actions
  • Price (USD)19.91
  • Today's Change0.63 / 3.27%
  • Shares traded138.00
  • 1 Year change-43.03%
  • Beta1.6891
Data delayed at least 20 minutes, as of Feb 10 2026 18:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

  • Revenue in USD (TTM)1.01bn
  • Net income in USD-203.37m
  • Incorporated2008
  • Employees2.65k
  • Location
    Tandem Diabetes Care Inc12400 High Bluff DriveSAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 366-6900
  • Fax+1 (302) 636-5454
  • Websitehttps://www.tandemdiabetes.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.